Cargando…
Recently published papers: predictors, pressors and poietins
Simple, sensitive and specific predictors of mortality in the critically ill remain elusive goals, and brain natriuretic peptide and venous lactate are the subjects of recent studies. The role of vasopressin in sepsis continues to be the focus of much research interest. Dose ranging studies, potenti...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246219/ https://www.ncbi.nlm.nih.gov/pubmed/18190727 http://dx.doi.org/10.1186/cc6188 |
_version_ | 1782150743320428544 |
---|---|
author | Ward, Suzannah Venn, Richard |
author_facet | Ward, Suzannah Venn, Richard |
author_sort | Ward, Suzannah |
collection | PubMed |
description | Simple, sensitive and specific predictors of mortality in the critically ill remain elusive goals, and brain natriuretic peptide and venous lactate are the subjects of recent studies. The role of vasopressin in sepsis continues to be the focus of much research interest. Dose ranging studies, potential adverse effects, and selective V1 agonists are discussed below in recent trials. Finally the use of erythropoietin in the critically ill continues to be studied but many continue to urge caution for widespread use outside of clinical trials. |
format | Text |
id | pubmed-2246219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22462192008-02-20 Recently published papers: predictors, pressors and poietins Ward, Suzannah Venn, Richard Crit Care Commentary Simple, sensitive and specific predictors of mortality in the critically ill remain elusive goals, and brain natriuretic peptide and venous lactate are the subjects of recent studies. The role of vasopressin in sepsis continues to be the focus of much research interest. Dose ranging studies, potential adverse effects, and selective V1 agonists are discussed below in recent trials. Finally the use of erythropoietin in the critically ill continues to be studied but many continue to urge caution for widespread use outside of clinical trials. BioMed Central 2007 2007-12-21 /pmc/articles/PMC2246219/ /pubmed/18190727 http://dx.doi.org/10.1186/cc6188 Text en Copyright © 2007 BioMed Central Ltd |
spellingShingle | Commentary Ward, Suzannah Venn, Richard Recently published papers: predictors, pressors and poietins |
title | Recently published papers: predictors, pressors and poietins |
title_full | Recently published papers: predictors, pressors and poietins |
title_fullStr | Recently published papers: predictors, pressors and poietins |
title_full_unstemmed | Recently published papers: predictors, pressors and poietins |
title_short | Recently published papers: predictors, pressors and poietins |
title_sort | recently published papers: predictors, pressors and poietins |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246219/ https://www.ncbi.nlm.nih.gov/pubmed/18190727 http://dx.doi.org/10.1186/cc6188 |
work_keys_str_mv | AT wardsuzannah recentlypublishedpaperspredictorspressorsandpoietins AT vennrichard recentlypublishedpaperspredictorspressorsandpoietins |